Neogen price target raised to $20 from $17 at Piper Sandler

Piper Sandler analyst David Westenberg raised the firm’s price target on Neogen to $20 from $17 and keeps a Neutral rating on the shares following the company’s earnings report. After having listened to the company’s webcast and followed up with management, he thinks "this will be the last reset" of estimates for FY23 and FY24, Westenberg tells investors.